Want to see TSE:PCLO full AI Analyst Report?
PCLO Stock Chart & Stats
C$0.08
-C$0.01(-13.33%)
At close: 4:00 PM EDT
C$0.08
-C$0.01(-13.33%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.17
Previous CloseN/A
Volume35.78K
Average Volume (3M)0.00
Market Cap
C$12.40M
Enterprise ValueC$26.82
Total Cash (Recent Filing)C$17.52K
Total Debt (Recent Filing)C$19.14M
Price to Earnings (P/E)―
Beta-3.82
Next Earnings
May 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding211,283,630
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Gross MarginA positive gross margin indicates the company’s products generate contribution before operating overhead. This provides a foundation for recovery if PharmaCielo can restore sales volume, improve scale, and control administrative and production costs.
Margin ImprovementImprovement from the 2023 cost and margin position suggests some operational progress. Although profitability remains inadequate, sustaining this trend could reduce losses and improve the viability of the cannabis-derived products platform over time.
Asset Base ExpansionGrowth in total assets indicates that the company retains or has expanded its operating resource base. This may support cultivation, extraction, and product-development activities, though the benefit depends on generating revenue from those assets.
Bears Say
Severe Balance-Sheet StressNegative equity and substantial debt relative to the company’s small operating scale indicate elevated solvency and refinancing risk. This limits financial flexibility and could constrain investment in cultivation, extraction, and commercial expansion.
Persistent Cash BurnOngoing negative operating and free cash flow means the business is not funding itself through operations. Continued cash consumption can increase dependence on financing, asset sales, or restructuring, weakening the company’s ability to sustain long-term growth.
Contracting Revenue And LossesVery low and sharply declining revenue, combined with deeply negative operating and net margins, shows that commercial scale remains insufficient. The company has not demonstrated a durable path to sustainable profitability despite some margin improvement.
PharmaCielo News
PCLO FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was C$0.04 and its highest was C$0.17 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is C$12.40M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is May 31, 2027 which is in 282 days.
How were PharmaCielo’s earnings last quarter?
Currently, no data Available
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 211,283,630 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in TSE:PCLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated medicinal products. Additionally, the company diversifies its offerings by providing telemedicine software. Its clientele spans a range of entities, such as health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies, across both Canada and Colombia. PharmaCielo also holds a strategic partnership with AssuredTrans Inc., and its corporate headquarters are situated in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―